Cidara Therapeutics Stock Market Value
| CDTX Stock | USD 18.58 0.48 2.65% |
| Symbol | Cidara |
Cidara Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cidara Therapeutics. If investors know Cidara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cidara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (23.90) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
The market value of Cidara Therapeutics is measured differently than its book value, which is the value of Cidara that is recorded on the company's balance sheet. Investors also form their own opinion of Cidara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cidara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cidara Therapeutics' market value can be influenced by many factors that don't directly affect Cidara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cidara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cidara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cidara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cidara Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cidara Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cidara Therapeutics.
| 01/02/2025 |
| 02/01/2025 |
If you would invest 0.00 in Cidara Therapeutics on January 2, 2025 and sell it all today you would earn a total of 0.00 from holding Cidara Therapeutics or generate 0.0% return on investment in Cidara Therapeutics over 30 days. Cidara Therapeutics is related to or competes with CytomX Therapeutics, Clearside Biomedical, and GlycoMimetics. Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long... More
Cidara Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cidara Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cidara Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.26 | |||
| Information Ratio | 0.1154 | |||
| Maximum Drawdown | 32.32 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 12.65 |
Cidara Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cidara Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cidara Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cidara Therapeutics historical prices to predict the future Cidara Therapeutics' volatility.| Risk Adjusted Performance | 0.1166 | |||
| Jensen Alpha | 0.7296 | |||
| Total Risk Alpha | 0.2652 | |||
| Sortino Ratio | 0.1288 | |||
| Treynor Ratio | 3.22 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cidara Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cidara Therapeutics Backtested Returns
Cidara Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Cidara Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of standard deviation over the last 3 months. By analyzing Cidara Therapeutics' technical indicators, you can evaluate if the expected return of 0.76% is justified by implied risk. Please makes use of Cidara Therapeutics' mean deviation of 4.06, and Risk Adjusted Performance of 0.1166 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cidara Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 0.23, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cidara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cidara Therapeutics is expected to be smaller as well. Please check Cidara Therapeutics' potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether Cidara Therapeutics' price patterns will revert.
Auto-correlation | 0.89 |
Very good predictability
Cidara Therapeutics has very good predictability. Overlapping area represents the amount of predictability between Cidara Therapeutics time series from 2nd of January 2025 to 17th of January 2025 and 17th of January 2025 to 1st of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cidara Therapeutics price movement. The serial correlation of 0.89 indicates that approximately 89.0% of current Cidara Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.89 | |
| Spearman Rank Test | 0.95 | |
| Residual Average | 0.0 | |
| Price Variance | 2.91 |
Cidara Therapeutics lagged returns against current returns
Autocorrelation, which is Cidara Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cidara Therapeutics' stock expected returns. We can calculate the autocorrelation of Cidara Therapeutics returns to help us make a trade decision. For example, suppose you find that Cidara Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cidara Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cidara Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cidara Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cidara Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Cidara Therapeutics Lagged Returns
When evaluating Cidara Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cidara Therapeutics stock have on its future price. Cidara Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cidara Therapeutics autocorrelation shows the relationship between Cidara Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Cidara Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.